Shenzhen Hepalink Pharmaceutical Group News

Shenzhen Hepalink Pharmaceutical Group: Hypry's 2023 Annual General Meeting of Shareholders Legal Opinion

May 23 00:00

Shenzhen Hepalink Pharmaceutical Group: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders

May 23 00:00

Shenzhen Hepalink Pharmaceutical Group: Announcement on Additional Provisional Proposals for the 2023 Annual General Meeting of Shareholders and Supplementary Notice to the Shareholders' Meeting

Apr 30 00:00

Hyperlink: Announcement of Joint Credit Assessment Co., Ltd. on terminating the credit ratings of Shenzhen Haipuri Pharmaceutical Group Co., Ltd. entities and related debts

Apr 8 15:49

Hyperion: Announcement on enoxaparin sodium preparations obtaining approval for drug registration in Thailand

Apr 3 00:00

Highpree: Special instructions for deducting operating income for 2023

Mar 30 00:00

Hyperion: Announcement on Using Own Funds to Purchase Wealth Management Products and Cash Management

Mar 29 00:00

Hyperion: Internal Control Self-Assessment Report

Mar 29 00:00

Hyperion: Report on the performance of supervisory duties of accounting firms by the Audit Committee of the Board of Directors in 2023

Mar 29 00:00

Highpree: 2023 Financial Results Report

Mar 29 00:00

Hyperion: Goodwill Impairment Test Report

Mar 29 00:00

Hapley: Announcement on Launching Foreign Exchange Derivatives Trading for Hedging Purposes

Mar 29 00:00

Hyperion: Shareholder return plan for the next three years (2024-2026)

Mar 29 00:00

Hyperion: Announcement on enoxaparin sodium preparations obtaining approval for drug registration in New Zealand

Mar 29 00:00

Hyperion: Announcement on the Company's 2023 Accrued Asset Impairment Preparation

Mar 29 00:00

Hypry: Notice of Annual General Meeting of Shareholders

Mar 29 00:00

Hyperlink: Announcement on receipt of advance payment from actual controller

Mar 16 00:00

Hyperlink: Third indicative announcement by Shenzhen Haipuri Pharmaceutical Group Co., Ltd. on exercising the redemption option of the issuer of the “22 Hyperui” corporate bonds

Feb 28 17:33

Hyperlink: Second indicative announcement by Shenzhen Haipuri Pharmaceutical Group Co., Ltd. on exercising the redemption option of the issuer of the “22 Hyperui” corporate bonds

Feb 27 17:01

Hyperlink: First indicative announcement by Shenzhen Haipuri Pharmaceutical Group Co., Ltd. on exercising the redemption option of the issuer of the “22 Hipry” corporate bonds

Feb 26 19:09